Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors.
Cao J, Ji D, Chen Z, Shen W, Wang J, Li B, Chi H, Long A, Gao L, Li J.
Cao J, et al. Among authors: long a.
Oncologist. 2017 Jun;22(6):638-e56. doi: 10.1634/theoncologist.2017-0137. Epub 2017 May 2.
Oncologist. 2017.
PMID: 28465370
Free PMC article.
Clinical Trial.
PK analyses indicated that ramucirumab had low clearance, small volume of distribution, and long half-life in Chinese patients, as in other populations. Immunogenicity was not detected. No patient had complete/partial response, and 64.3% (n = 18) had stable disease with …
PK analyses indicated that ramucirumab had low clearance, small volume of distribution, and long half-life in Chinese patients, as in …